BioAge Labs, Inc

Healthcare · Drug Manufacturers - Specialty & Generic · —

7.20$ -8.6% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

BioAge Labs, Inc (BIOA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 397 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet BIOA
Line item	Q1 13	Q2 13	Q3 13	Q4 13	Q1 14	Q2 14	Q3 14	Q4 14	Q1 15	Q2 15	Q3 15	Q4 15	Q1 16	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	44	124	119	114	117	119	162	152	144	190	173	143	158	149	158	161	151	148	156	70	–	–	–	26	180	164	337	358	344	322	305	295	398	397
Current Assets	27	114	107	95	85	66	87	57	31	55	38	11	20	12	23	31	21	16	20	15	28	–	–	25	179	164	336	357	325	302	291	287	392	330
Cash	12	103	96	84	73	54	79	51	26	49	34	7.0	14	5.5	16	16	5.3	5.7	10	4.6	28	–	–	22	174	159	334	354	257	220	216	189	242	74
Cash & Short-Term Investments	12	103	96	84	73	54	79	51	26	49	34	7.0	14	5.5	16	16	5.3	5.7	10	4.6	28	–	–	22	174	159	334	354	321	297	286	281	383	319
Receivables	0.6	0.6	0.6	0.8	0.6	0.6	0.3	0.5	0.4	0.4	0.2	1.0	1.4	2.2	4.0	1.0	0.3	3.7	2.5	4.9	–	–	–	–	–	–	–	0.0	0.4	0.6	0.5	0.8	0.7	0.6
Inventory	3.2	2.3	2.8	2.4	3.9	4.0	3.0	1.8	2.0	1.3	1.3	1.7	2.2	2.8	2.5	4.5	4.8	4.9	6.2	4.8	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.6	0.7	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	12	4.2	4.2	4.2	4.2	4.2	4.3	4.3	5.5	5.3	6.4	6.4	6.3	6.2	6.2	6.1	6.1	6.0	6.0	4.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	16	45	47	49	71	83	100	95	97	122	118	97	105	90	105	113	86	79	49	48	-20	–	–	199	365	362	24	35	31	27	28	23	19	22
Current Liabilities	11	10	13	18	24	32	34	23	26	35	35	30	19	19	29	45	18	10	19	11	–	–	–	58	15	13	19	28	24	23	24	20	16	19
Short-Term Debt	1.0	1.0	3.1	6.5	9.9	13	12	3.0	6.1	12	15	10	10	10	24	23	3.5	4.3	12	4.9	–	–	–	45	6.3	6.3	6.3	6.2	6.7	6.2	4.7	3.2	1.8	0.7
Accounts Payable	0.5	0.1	0.2	0.0	0.5	2.6	0.9	1.0	17	17	16	16	4.7	5.1	5.5	6.0	4.6	5.9	6.8	6.2	–	–	–	1.9	2.3	1.5	2.1	2.0	4.0	1.3	5.0	2.7	3.1	5.7
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	8.2	6.8	5.4	3.9	2.5	1.1	–	–	–	–	–
Shareholders' Equity	27	79	72	65	46	36	62	58	48	68	55	46	52	58	53	48	65	69	107	22	20	–	–	-173	-186	-197	314	323	313	295	277	272	379	375
Retained Earnings	-91	-97	-106	-115	-135	-149	-157	-161	-170	-184	-190	-198	-209	-204	-211	-221	-221	-228	-235	-319	–	–	–	-182	-195	-208	-232	-253	-266	-287	-307	-333	-356	-382
Shares Outstanding	28	28	28	28	28	28	28	28	28	28	28	28	28	28	34	34	34	35	42	42	34	34	34	34	34	34	34	36	36	36	36	36	42	45

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings